Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
about
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsSafety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.Emerging gliptins for type 2 diabetes.Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study.Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapyAssociation between Use of Oral Anti-Diabetic Drugs and the Risk of Sepsis: A Nested Case-Control StudyLinagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials.Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatmentDipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.A review of gliptins in 2011.The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.Red carpeting the newer antidiabetics.Recent advances in incretin-based therapies.The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.Association of musculoskeletal complaints and gliptin use: review of spontaneous reports.The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.DPP-4 inhibitors: pharmacological differences and their clinical implications.DPP-4 inhibitors: focus on safety.Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study.Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes.Validation and incidence of community-acquired pneumonia in patients with type 2 diabetes in the BIFAP database.Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.CD26 and Asthma: a Comprehensive Review.DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs.Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs.Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes
P2860
Q26778608-5E8FE011-D585-4918-B15C-4977164024F8Q34135837-4804ACE8-D403-406D-BAA1-F643C76D6CB1Q34347884-06A6D2D4-2AE9-446E-B6E6-6C275296A9ACQ35808043-0D25F179-99EB-4AC5-AC84-5235E152EF7EQ35979834-CA7052FF-0ABF-4851-9376-B9C9D4F7C163Q36158762-BB1F1E0D-6699-4464-8B9C-36E3ABE76DACQ36401258-1167E276-8E8C-4485-AE34-C06967BE1D55Q36792608-EAEF6DC0-F4F4-4755-AD9B-B6DEE7CCB845Q36942108-FA84AAE4-1126-42C2-842A-9A5C56FE1618Q37195882-794AF274-8D11-4948-8849-593485AEBA28Q37965612-282816E6-ECFD-4519-BFBF-186C52693DD9Q37984756-70E16834-76E9-4A46-B423-34E751C01588Q37992956-8CD27859-C9A9-4F53-B6DF-024D52768A6BQ38004088-672C6598-8B5B-4C3D-B72E-DB078BF0D5DFQ38013105-35EE0385-98F4-4A5A-99BF-AA5C1E2B7F4CQ38026956-66D73804-7630-42AD-8F43-7343A89A9340Q38088195-546904E2-41D9-4269-8519-AAEB600B9311Q38107546-66D98DF6-3BF3-4E07-A971-D7DF98A99DA4Q38130192-AA7B39F8-C199-4ABF-AD06-0F443F3F8C24Q38211881-89600B47-150C-4F76-8E94-FAD0B276728BQ38212472-64B12ABE-F4BE-47CD-AAC1-4D2C6D0B05A6Q38244576-B28C767E-87E2-41B7-AC71-1E0649079AA9Q38285608-E2129AB5-B5DF-4D38-9ED2-74579CE8810DQ38402241-DBF1DA25-FE8E-4B2B-9A7B-3BA8432583DAQ38416814-5EC19104-BFDC-4550-8EC7-FDF0F65DF7D7Q38601821-03464482-850B-4A71-B0E7-CBDC6C8365B5Q38751579-D9E35D29-524F-4DEF-A813-BA038AA2C549Q38758454-312D475E-C112-4D5A-BBDF-9CF963D50958Q38937243-E4061B92-AA2D-40DD-AC4D-ED0C215D9E24Q40487459-CE23F670-0FB4-4AAE-A0C1-DEF3AD7A7D27Q41784210-6B15FBF3-E1DD-4C00-B679-CA9367E26077Q43470326-CB616E06-E36B-4712-8197-D4ADC6471D81Q46643138-6CAF6201-96E8-4453-9914-B434D39CCE3BQ47574418-464A79C7-122D-4021-9B18-871A9FC73C06Q57477167-A2DC4280-FDD2-4F0F-A2C4-E6FEF012672A
P2860
Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Use of dipeptidyl peptidase-4 ...... Health Organization VigiBase.
@ast
Use of dipeptidyl peptidase-4 ...... Health Organization VigiBase.
@en
Use of dipeptidyl peptidase-4 ...... Health Organization VigiBase.
@nl
type
label
Use of dipeptidyl peptidase-4 ...... Health Organization VigiBase.
@ast
Use of dipeptidyl peptidase-4 ...... Health Organization VigiBase.
@en
Use of dipeptidyl peptidase-4 ...... Health Organization VigiBase.
@nl
prefLabel
Use of dipeptidyl peptidase-4 ...... Health Organization VigiBase.
@ast
Use of dipeptidyl peptidase-4 ...... Health Organization VigiBase.
@en
Use of dipeptidyl peptidase-4 ...... Health Organization VigiBase.
@nl
P2093
P2860
P356
P1433
P1476
Use of dipeptidyl peptidase-4 ...... Health Organization VigiBase.
@en
P2093
Aukje K Mantel-Teeuwisse
Hubert G Leufkens
Marjolein J Willemen
Ron H Meyboom
Sabine M Straus
P2860
P304
P356
10.2337/DC10-1771
P407
P577
2011-02-01T00:00:00Z